Vaccine strategies to treat lymphoproliferative disorders
References (288)
- et al.
Dendritic cells in multiple myeloma immunotherapy
Cytotherapy
(2004) - et al.
Graft-versus-myeloma effect in two cases
Lancet
(1996) Dendritic cells: unique leukocyte populations which control the primary immune response
Blood
(1997)- et al.
Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer
J Urol
(2004) - et al.
On the road to a tumor cell vaccine: 20 years of cellular immunotherapy
Vaccine
(2004) - et al.
Dendritic cells: limited potential in immunotherapy
Int J Biochem Cell Biol
(2005) Dendritic cells and their emerging clinical applications
Pathology
(2001)- et al.
Differential production of inflammatory chemokines by murine dendritic cell subsets
Immunobiology
(2004) Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets
Blood
(2002)- et al.
Blood monocytes consist of two principal subsets with distinct migratory properties
Immunity
(2003)
Danger signals: SOS to the immune system
Curr Opin Immunol
Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells
Blood
CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells
Immunity
The role of CD4+ T cell responses in antitumor immunity
Curr Opin Immunol
NKT cells conductors of tumor immunity?
Curr Opin Immunol
Immunotherapy and immunoselection-tumour escape as the final hurdle
FEBS Lett
The makings of a tumor rejection antigen
Immunity
Is cancer dangerous to the immune system?
Semin Immunol
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy
Immunity
Lymphoid reconstitution after autologous PBSC transplantation with FACS- sorted CD34+ hematopoietic progenitors
Blood
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
Blood
Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans
Blood
Sperm protein 17 (Spl 7) is a suitable target for immunotherapy of multiple myeloma
Blood
Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin lymphoma patients
Exp Hematol
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- beta(l) and interleukin-10
Blood
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Blood
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression
Blood
Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation
Blood
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes
Blood
Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma
Immunol Cell Biol
DC-based immunotherapy of B-cell malignancies
Cytotherapy
Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells
Hematology
Predicting long-term (> or =5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
Br J Haematol
Dendritic cells and the control of immunity
Nature
Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells
World J Gastroenterol
Dendritic cells: On the move from bench to bedside
Nat Med
Immunobiology of dendritic cells
Annu Rev Immunol
Mouse and human dendritic cell subtypes
Nat Rev Immunol
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Nat Rev Immunol
The phenotype of freshly isolated and cultured human bone marrow allostimulatory cells: possible heterogeneity in bone marrow dendritic cell populations
Immunology
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and down- regulated by tumor necrosis factor alpha
J Exp Med
Proliferating dendritic cell progenitors in human blood
J Exp Med
Idiotypic vaccination as therapy for multiple myeloma
Semin Hematol
Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells
Int Immunol
The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting
J Exp Med
Cell biology of antigen processing in vitro and in vivo
Annu Rev Immunol
Toll-like receptor control of the adaptive immune responses
Nat Immunol
The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation
J Immunol
Immunotherapy of hormone- refractory prostate cancer with antigen-loaded dendritic cells
J Clin Oncol
Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Thl development
Eur J Immunol
Cited by (13)
Dendritic Cells in Cancer Immunotherapy
2008, Advances in Cancer ResearchCitation Excerpt :In the tissues, MDC include Langerhans cells that are generally found in the epidermis, oral‐respiratory and genital mucosa, and the interstitial DCs present in other tissues. PDC reside mainly in the blood and lymphoid organs (Banchereau and Palucka, 2005; Radford et al., 2005b). Monocyte‐derived DCs (MoDCs) can be generated in vitro by culturing monocytes in the presence of granulocyte/macrophage‐colony stimulating factor (GM‐CSF) and interleukin‐4 (IL‐4) or other cytokines.
Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205
2007, VaccineCitation Excerpt :During this process, DC migrate into lymph nodes and display the processed antigens to T lymphocytes, thereby eliciting antigen-specific immune responses or tolerance/anergy, depending on the presence or absence of additional costimulatory/tolerogenic signals. Successful delivery of antigens into DC both in vitro and in vivo is a key step for successful vaccination against infectious diseases, cancer and autoimmune diseases [3–5]. A new strategy, which targets DC cell surface proteins, particularly their specialized antigen-loading receptors, has recently been described in mouse models [6–8].
Lymphoproliterative disorders
2005, PathologyPhysical activity and hematologic cancer prevention
2011, Recent Results in Cancer ResearchPractical blood dendritic cell vaccination for immunotherapy of multiple myeloma
2008, British Journal of HaematologyThe anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
2008, Nature Medicine